Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.65 |
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27176263 | 0.97 | ALDH1A1 (0.64) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27176309 | 0.96 | ALDH1A1 (0.62) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1178309 | 0.94 | ALDH1A1 (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27176248 | 0.87 | RAB9A (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1178518 | 0.86 | NPC1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1178605 | 0.86 | RAB9A (0.65) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16373630 | 0.85 | LMNA (0.69) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1178548 | 0.84 | ALDH1A1 (0.64) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1178492 | 0.84 | NPC1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15190451 | 0.84 | ALDH1A1 (0.44) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518978-B2 | Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-27 | — | — | US | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | disclosed |
| US-8518978-B2 | Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-27 | — | — | US | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | PTGIR, GPR119, PTGIS | NPC1 1805/4885RAB9A 2717/4885ALDH1A1 957/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | NPC1 2242/4885RAB9A 2013/4885ALDH1A1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.